FDA, CDC experts: What physicians need to know about tecovirimat (TPOXX) for treatment of monkeypox, Part 1

Experts from the AMA, FDA and CDC discuss tecovirimat, or TPOXX, for the treatment of monkeypox in infected individuals. The discussion provides background on tecovirimat, including its current status, availability and access while the drug is under an investigational new drug application. Guests include Adam Sherwat, MD, Deputy Director, Office of Infectious Disease at FDA’s Center for Drug Evaluation and Research; Brett W. Petersen, MD, MPH, Deputy Chief, Poxvirus and Rabies Branch, CDC’s Division of High-Consequence Pathogens and Pathology; and Timothy Wilkin, MD, MPH, Professor of Medicine and Assistant Dean for Clinical Research Compliance for Human Research Protections at Weill Cornell Medicine and TPOXX clinical trial lead.     ⭐⭐⭐⭐⭐ 🩺 The AMA is your powerful ally, focused on addressing the issues important to you, so you can focus on what matters most — patients. We will meet this challenge together. Join us: https://ama-assn.co/JoinRenew  🥼 Go to https://ama-assn.co/FightingForDocs to learn more about our AMA advocacy priorities, including:  ▹ Reforming Medicare payment  ▹ Fighting scope creep  ▹ Fixing prior authorization  ▹ Reducing physician burnout  ▹ Making technology work for physicians  📺 Subscribe to @americanmedicalassociation on YouTube: https://ama-assn.co/youTube  📧 Sign up for #MorningRounds and free daily newsletters from the AMA: https://ama-assn.co/Newsletters  💬 Follow #AMA on social media: https://ama-assn.co/Social